Gastrointestinal Cancer

2022 ASCO Gastrointestinal Cancers Symposium Highlights

April 20, 2022

Ivosidenib maintains quality of life in cholangiocarcinoma, immunotherapy outperforms chemotherapy in select gastric/gastroesophageal junction adenocarcinoma, and nivolumab induces high response rates are observed among patients with BRAF V600E–mutant metastatic colorectal cancer.